Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA panel backs gene therapy for rare blindness form

Spark Therapeutics Inc.’s experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded, paving the way for the first U.S. gene therapy for an inherited disease.

Read More »

Spark gene therapy improves vision, at least in short term: FDA

Spark Therapeutics Inc.’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.

Read More »

7 Juicy Acquisition Targets in Biopharma for 2017

2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.

Read More »

Regeneron Bets $315 Million on Ocular Therapeutix for an Upgraded Form of Eylea

Ocular Therapeutix struck a deal worth up to $315 million to develop a new formulation of Regeneron Pharmaceuticals’ approved drug Eylea.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation